Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice (original) (raw)
References
Acquas E, Carboni E, de Ree RH, Da Prada M, Di Chiara G (1992) Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592. J Neurochem 59: 326–330 Google Scholar
Archer T, Fredriksson A, Jonsson G, Lewander T, Mohammed AK, Ross SB, Söderberg U (1986) Central noradrenaline depletion antagonizes aspects of d-amphetamineinduced hyperactivity in the rat. Psychopharmacology (Berl) 88: 141–146 Google Scholar
Barbeau A (1969) L-Dopa therapy in Parkinson's disease: a critical review of nine year's experience. Can Med Assoc J 101: 59–68 Google Scholar
Barbeau A (1971) Long-term side-effects of levodopa. Lancet 1: 395 Google Scholar
Birkmayer W, Knoll J, Riederer P, Youdim MBH (1983) (−) Deprenyl leads to prolongation of L-DOPA efficacy in Parkinson's disease. Mod Probl Pharmacopsychiatry 19: 170–176 Google Scholar
Birkmayer W, Riederer PM, Hars V, Marton J (1985) Improvement of life expectancy due to L-Deprenyl addition to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm 64: 113–127 Google Scholar
Birkmayer W, Riederer PM, Youdim MBH, Linauer W (1975) The potentiation of the anti-kinetic effect after L-DOPA treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 36: 303–326 Google Scholar
Brannan T, Martinez-Tica J, Yahr MD (1992) Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats. Neurology 42: 683–685 Google Scholar
Cedarbaum JM, Leger G, Guttman M (1991) Reduction of circulating 3-O-methyltdopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease. Clin Neuropharmacol 14: 330–342 Google Scholar
Cedarbaum JM, Leger G, Reches A, Guttman M (1990) Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys. Clin Neuropharmacol 13: 544–552 Google Scholar
Chrisp P, Mammen GJ, Sorkin EM (1991) Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging 1: 228–248 Google Scholar
Da Prada M (1991) New approaches to the treatment of age-related brain disorders. Can J Neurol Sci 18: 384–386 Google Scholar
Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1: 249–254 Google Scholar
Drago F, Continella G, Spadaro F, Cavaliere S, Scapagnini U (1986) Behavioral effects of deprenyl in aged rats. Funct Neurol 1: 165–174 Google Scholar
Engberg G, Elebring T, Nissbrandt H (1991) Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. J Pharmacol Exp Ther 259: 841–847 Google Scholar
Fahn S, Comi R, Snider SR, Prasad ALN (1979) Effect of a catechol-O-methyl transferase inhibitor, U-0521; with levodopa administration. Biochem Pharmacol 28: 1221–1225 Google Scholar
Forna KS (1982) Pathology of Parkinson's disease. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth Scientific, London, pp 25–40 Google Scholar
Fredriksson A, Archer T (1994) MPTP-induced behavioural and biochemical deficits: a paramatric analysis. J Neural Transm 7: 123–132 Google Scholar
Fredriksson A, Plaznik A, Sundström E, Jonsson G, Archer T (1990) MPTP-induced hypoactivity in mice: reversal by L-dopa. Pharmacol Toxicol 67: 295–301 Google Scholar
Gervas J, Muradas B, Bazan E, Aquado E, de Yebenes J (1983) Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 33: 278–282 Google Scholar
Goldstein M, Lieberman A (1992) The role of the regulatory enzymes of catecholamine synthesis in Parkinson's disease. Neurology 42: 8–12 Google Scholar
Guttman M, Leger G, Reches A, Evans A, Kuwabara H, Cedarbaum JM, Gjedde A (1993) Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Mov Disord 8: 298–304 Google Scholar
Heikkila RE, Cabbat FS, Manzino L, Duvoisin RC (1981) Potentiation by deprenil of L-dopa induced circling in nigral lesioned rats. Pharmacol Biochem Behav 15: 75–79 Google Scholar
Heikkila RE, Sieber B-A, Manzino L, Sonsalla PK (1989) Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Mol Chem Neuropathol 10: 171–183 Google Scholar
Heinonen EH, Lammintausta R (1991) A review of the pharmacology of selegiline. Acta Neurol Scand [Suppl] 136: 44–59 Google Scholar
Heinonen EH, Myllylä V, Sotaniemi K, Lamintausta R, Salonen JS, Anttila M, Savijärvi M, Kotila M, Rinne UK (1989) Pharmacokinetics and metabolism of selegiline. Acta Neurol Scand 80 [Suppl 126]: 83–91 Google Scholar
Hietanen MH (1991) Selegiline and cognitive function in Parkinson's disease. Acta Neurol Scand 84: 407–410 Google Scholar
Jonsson G, Hallman H, Mefford I, Adams RN (1980) The use of liquid chromamatography with electrochemical detection for the determination of adrenaline and other biogenic amines in the CNS. In: Fuxe K, Goldstein M, Hökfelt B, Hökfelt T (eds) Central adrenaline neurones. Pergamon Press, Oxford, pp 59–71 Google Scholar
Kaakkola S, Wurtman RJ (1992) Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study. Brain Res 587: 241–249 Google Scholar
Kaakkola S, Teravainen H, Ahtila S, Rita H, Gordin A (1994) Effect of entacapone, a COMT inhibitor, on clinical disability and L-Dopa metabolism in parkinsonian patients. Neurology 44: 77–80 Google Scholar
Karoum F, Chuang L-W, Eisler T, Calne DB, Liebowitz MR, Quitkin FM, Klein DF, Wyatt RJ (1982) Metabolism of (−) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biological assessment. Neurology 32: 503–509 Google Scholar
Keller R, Oke A, Mefford I, Adams RN (1976) Liquid chromatographic analysis of the catecholamines — routine assay for regional brain mapping. Life Sci 19: 995–1004 Google Scholar
Keranen T, Gordin A, Harjola VP, Karlsson M, Korpela K, Pentikainen PJ, Rita H, Seppala L, Wikberg T (1993) The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 16: 145–156 Google Scholar
Kirk RE (1968) Experimental design. Procedures in behavioural science. Belmont CA, Brooks/Cole Inc Google Scholar
Knoll J (1978) The possible mechanisms of action of (−) deprenyl in Parkinson's disease. J Neural Transm 43: 177–198 Google Scholar
Knoll J (1987) (−) Deprenyl (selegiline, MoverganR) facilitates the activity of the nigrostriatal neuron. J Neural Transm [Suppl 25]: 45–66 Google Scholar
Knoll J (1989) The pharmacology of selegiline [(−) deprenyl]. New aspects. Acta Neurol Scand 80 [Suppl 126]: 83–91 Google Scholar
Knoll J (1992) Pharmacological basis of the therapeutic effect of (−) deprenyl in agerelated neurological diseases. Med Res Rev 12: 505–524 Google Scholar
Laihinen A, Rinne JO, Rinne UK, Haaparanta M, Ruotsalainen U, Bergman J, Solin O (1992) [18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462). Neurology 42: 199–203 Google Scholar
Langsten JW, Ballard P, Tetrud JW, Irwin I (1983) Chronoic parkinsonism in humans due to a product of meperidine analog. Science 219: 979–980 Google Scholar
Lees AJ, Shaw KM, Kohout LJ, Stern GM, Elsworth JD, Sandler M, Youdim MBH (1977) Deprenyl in Parkinson's disease. Lancet 2: 791–796 Google Scholar
LeWitt PA (1991) Deprenyl's effect at slowing progression of parkinsonian disability: the DATATOP study. The Parkinson Study Group. Acta Neurol Scand [Suppl 136]: 79–86 Google Scholar
Limousin P, Pollak P, Gervason-Tournier CL, Hommel M, Perret JE (1993) Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease. Lancet 341: 1605 Google Scholar
Lindén I-B, Etemadzedah E, Schultz E, Pohto P (1990) Selective catachol-O-methyltransferase inhibition as potential adjunctive treatment with L-dopa in Parkinson's disease. Mov Disord 5: 49 Google Scholar
Maj J, Rogoz Z, Skuza G, Sowinska H, Superata J (1990) Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease. J Neural Transm [P-D Sect] 2: 101–112 Google Scholar
Männistö P, Kaakkola S (1990) Rationale for selective COMT inhibitors as adjuncts in the treatment of Parkinson's disease. Pharmacol Toxicol 66: 317–323 Google Scholar
Männistö PT, Tuomainen P, Toivonen M, Tornwall M, Kaakkola S (1990) Effect of acute levodopa on brain catecholamines after selective MAO and COMT inhibition in male rats. J Neural Transm [P-D Sect] 2: 31–43 Google Scholar
Muenter M, Sharpless N, Tyce G (1972) Plasma 3-O-methyldopa in L-dopa therapy of Parkinson's disease. Mayo Clin Proc 47: 389–395 Google Scholar
Nakashima H, Asari S, Nishimoto A, Goldstein M (1991) The effect of chronic treatment of deprenyl in animal models of Parkinson's disease. No To Shinkei 43: 357–361 Google Scholar
Nomoto M, Fukuda T (1993) A selective MAO-B inhibitor Ro19-6327 potentiates the effects of levodopa on parkinsonism induced by MPTP in the common marmoset. Neuropharmacology 32: 473–477 Google Scholar
Nutt J, Woodward W (1987) 3-O-Methyldopa and the response to levodopa. Ann Neurol 21: 584–588 Google Scholar
Nuutila J, Kaakkola S, Männistö PT (1987) Potentiation of central effects of L-dopa by an inhibitor of catechol-O-methyltransferase. J Neural Transm 70: 233–240 Google Scholar
Okuda C, Segal DS, Kuczenski P (1992) Deprenyl alters behavior and caduate dopamine through an amphetamine-like action. Pharmacol Biochem Behav 43: 1075–1080 Google Scholar
Reches A, Fahn S (1982) 3-O-Methyldopa blocks dopa metabolism in rat corpus striatum. Ann Neurol 12: 267–271 Google Scholar
Reches A, Fahn S (1984) Catechol-O-methyltransferase and Parkinson's disease. Adv Neurol 40: 171–178 Google Scholar
Reches A, Miekle L, Fahn S (1982) 3-O-Methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway. Neurology 32: 887–888 Google Scholar
Reynolds JP, Elsworth JD, Blau K, Sandler M, Lees AJ, Stern GM (1978) Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Parmacol 6: 543–544 Google Scholar
Rinne UK (1989) Combination of a dopamine agonist, MAO-B inhibitor and levodopa — a new strategy in the treatment of early Parkinson's disease. Acta Neurol Scand [Suppl 126]: 165–169 Google Scholar
Rinne UK, Surtola T, Sonniven V (1978) L-Deprenyl treatment of on-off phenomena in Parkinson's disease. J Neural Transm 43: 253–262 Google Scholar
Selby G (1968) Parkinson's disease. In: Vinken PJ, Bruyn GW (eds) Handbook of clinical neurology. North-Holland, Amsterdam, pp 173–211 Google Scholar
Sharpless N, Muenter M, Tyce G (1972) 3-Methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease. Clin Chim Acta 37: 359–369 Google Scholar
Sonsalla PK, Heikkila RE (1986) The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur J Pharmacol 129: 339–345 Google Scholar
Teravainen H (1990) Selegiline in Parkinson's disease. Acta Neurol Scand 81: 333–336 Google Scholar
Tetrud JW, Langston JW (1989) The effect of deprenyl (Selegiline) on the natural history of Parkinson's disease. Science 245: 519–522 Google Scholar
Timar J, Knoll B, Knoll J (1992) (−) Deprenyl is devoid of amphetamine-like behavioural effects in rats. Acta Physiol Hung 79: 131–137 Google Scholar
Timar J, Gyarmati Z, Tekes K, Harsing GL, Knoll J (1993) Further proof that (−) deprenyl fails to facilitate mesolimbic dopaminergic activity. Pharmacol Biochem Behav 46: 709–714 Google Scholar
Walton J (1985) Brain's diseases of the nervous system, 9th ed. Oxford University Press, New York Google Scholar
Weihmüller FB, Hadjiconstantinou M, Bruno JP (1989) Dissociation between the biochemical and behavioural recovery in MPTP-treated mice. Pharmacol Biochem Behav 34: 113–117 Google Scholar
Yasar S, Schindler CW, Thorndike EB, Szelenyi I, Goldberg SR (1993) Evaluation of the stereoisomers of deprenyl for amphetamine-like discriminative stimulus effects in rats. J Pharmacol Exp Ther 265: 1–6 Google Scholar
Yoshida T, Oguro T, Kuroiwa Y (1987) Hepatic and extrahepatic metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor, of amphetamines in rats: sex and strain differences. Xenobiotica 17: 957–963 Google Scholar
Yoshida T, Yamada Y, Yamamoto T, Kuroiwa Y (1986) Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency. Xenobiotica 16: 129–136 Google Scholar
Zurcher G, Colzi A, Da Prada M (1990) Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. J Neural Transm [Suppl 32]: 375–380 Google Scholar